LPL Financial’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.5M | Buy |
62,420
+18,495
| +42% | +$2.74M | ﹤0.01% | 2096 |
|
|
2026
Q1 | $5.79M | Buy |
43,925
+3,602
| +9% | +$478K | ﹤0.01% | 2496 |
|
|
2025
Q4 | $5.72M | Buy |
40,323
+6,133
| +18% | +$889K | ﹤0.01% | 2417 |
|
|
2025
Q3 | $4.8M | Buy |
34,190
+4,520
| +15% | +$612K | ﹤0.01% | 2492 |
|
|
2025
Q2 | $3.73M | Buy |
29,670
+13,355
| +82% | +$1.53M | ﹤0.01% | 2552 |
|
|
2025
Q1 | $1.8M | Sell |
16,315
-439
| -3% | -$55.6K | ﹤0.01% | 3038 |
|
|
2024
Q4 | $2.29M | Buy |
16,754
+3,643
| +28% | +$451K | ﹤0.01% | 2740 |
|
|
2024
Q3 | $1.51M | Buy |
13,111
+783
| +6% | +$107K | ﹤0.01% | 2998 |
|
|
2024
Q2 | $1.7M | Sell |
12,328
-232
| -2% | -$31.8K | ﹤0.01% | 2755 |
|
|
2024
Q1 | $1.73M | Buy |
12,560
+2,733
| +28% | +$373K | ﹤0.01% | 2657 |
|
|
2023
Q4 | $1.29M | Buy |
9,827
+13
| +0.1% | +$1.5K | ﹤0.01% | 2825 |
|
|
2023
Q3 | $1.1M | Buy |
9,814
+1,600
| +19% | +$168K | ﹤0.01% | 2810 |
|
|
2023
Q2 | $775K | Buy |
8,214
+21
| +0.3% | +$2.05K | ﹤0.01% | 3073 |
|
|
2023
Q1 | $829K | Sell |
8,193
-3,016
| -27% | -$314K | ﹤0.01% | 2898 |
|
|
2022
Q4 | $1.34M | Sell |
11,209
-4,278
| -28% | -$501K | ﹤0.01% | 2414 |
|
|
2022
Q3 | $1.65M | Sell |
15,487
-1,481
| -9% | -$150K | ﹤0.01% | 2136 |
|
|
2022
Q2 | $1.65M | Sell |
16,968
-1,157
| -6% | -$107K | ﹤0.01% | 2174 |
|
|
2022
Q1 | $1.7M | Sell |
18,125
-1,298
| -7% | -$110K | ﹤0.01% | 2187 |
|
|
2021
Q4 | $1.65M | Sell |
19,423
-1,384
| -7% | -$127K | ﹤0.01% | 2232 |
|
|
2021
Q3 | $2M | Buy |
20,807
+6,644
| +47% | +$628K | ﹤0.01% | 2046 |
|
|
2021
Q2 | $1.38M | Buy |
14,163
+7,654
| +118% | +$734K | ﹤0.01% | 2297 |
|
|
2021
Q1 | $633K | Sell |
6,509
-2,035
| -24% | -$213K | ﹤0.01% | 2823 |
|
|
2020
Q4 | $819K | Buy |
8,544
+690
| +9% | +$66.6K | ﹤0.01% | 2344 |
|
|
2020
Q3 | $755K | Buy |
7,854
+1,670
| +27% | +$193K | ﹤0.01% | 2149 |
|
|
2020
Q2 | $754K | Buy |
6,184
+386
| +7% | +$42.7K | ﹤0.01% | 2057 |
|
|
2020
Q1 | $502K | Sell |
5,798
-201
| -3% | -$19.7K | ﹤0.01% | 2102 |
|
|
2019
Q4 | $645K | Buy |
5,999
+2,614
| +77% | +$274K | ﹤0.01% | 2158 |
|
|
2019
Q3 | $305K | Sell |
3,385
-217
| -6% | -$20.3K | ﹤0.01% | 2661 |
|
|
2019
Q2 | $304K | Sell |
3,602
-949
| -21% | -$77.9K | ﹤0.01% | 2690 |
|
|
2019
Q1 | $401K | Buy |
4,551
+657
| +17% | +$54.9K | ﹤0.01% | 2402 |
|
|
2018
Q4 | $278K | Buy |
+3,894
| New | +$373K | ﹤0.01% | 2525 |
|
|
2013
Q4 | – | Sell |
-19,699
| Closed | -$202K | – | 2676 |
|
|
2013
Q3 | $202K | Buy |
+19,699
| New | +$271K | ﹤0.01% | 2316 |
|
Other funds holding NBIX
LPL Financial's NBIX Position: Q2 2026 in Review
LPL Financial increased its Neurocrine Biosciences (NBIX) stake by 42% in Q2 2026, buying an estimated $2.74M and bringing the position to 62,420 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2096.
LPL Financial first reported a position in NBIX in Q3 2013 and has held it in 32 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- LPL Financial held 62,420 shares of Neurocrine Biosciences worth $10.5M as of Q2 2026.
- LPL Financial bought 18,495 Neurocrine Biosciences shares in Q2 2026, an estimated $2.74M.
- Neurocrine Biosciences made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #2096 holding.
- LPL Financial first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 32 quarters since.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.